Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

Inclusion Criteria: * Primary or de novo MDS * Low or intermediate-1 MDS * ECOG performance status 0 or 1 * Documented significant anemia with or without neutropenia and/or thrombocytopenia * Adequate kidney and liver function * Patients must have discontinued hematopoietic growth factors at least 3 weeks prior to study entry Exclusion Criteria: * Prior allogenic bone marrow transplant for MDS * History of MDS IPSS score greater than 1.0 * Pregnant or lactating women * Any severe concurrent disease, infection, or comorbidity that, in the judgement of the investigator, would make the patient inappropriate for study entry * Oral steroids e.g. prednisone \>10 mg per day * History of active hepatitis B or C * Known history of HIV